ACRX - Acelrx Pharmaceuticals Inc.

ACRX Stock Chart

ACRX Profile

AcelRx Pharmaceuticals, Inc., a specialized pharmaceutical company headquartered in Hayward, California, focuses on advancing therapies for the treatment of acute pain. The company's primary focus is on DSUVIA and DZUVEO, its lead product candidates consisting of 30 mcg sufentanil sublingual tablets designed to manage moderate-to-severe acute pain effectively. AcelRx also pioneers innovative solutions like ZALVISO, a patient-controlled analgesia system enabling hospitalized patients to self-administer sufentanil sublingual tablets for acute pain management.

In addition to its established products, AcelRx Pharmaceuticals continues to expand its pipeline with promising candidates. These include ARX-02, currently undergoing Phase 2 clinical trials for the treatment of cancer breakthrough pain in opioid-tolerant patients, and 4ARX-03, targeted for mild sedation and pain relief during medical procedures. The company's diversified portfolio further includes Niyad, a regional anticoagulant for extracorporeal circuits, and LTX-608, a nafamostat formulation under investigation for potential applications in treating COVID-19, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis.

Founded in 2005 as SuRx, Inc., and later rebranded as AcelRx Pharmaceuticals, Inc., in August 2006, the company remains committed to innovation and clinical excellence in acute pain management. With a strategic focus on enhancing patient outcomes through advanced pharmaceutical solutions, AcelRx Pharmaceuticals continues to drive advancements in pain relief therapies worldwide.

ACRX Revenue Chart

ACRX Earnings

Analyst Ratings